Welcome to the
IdISBa Cancer Epigenetics Lab
We are the Cancer Epigenetics Lab, at the Cancer Cell Biology Group. Our lab is focused on studying epigenetic alterations involved in aggressive cancer traits. Our projects are based on the combination of bioinformatics tools, such as Machine Learning and Artificial Intelligence, and wet lab involving genome editing and multi-omics profiling.
Our goal is to translate basic research into the beachside, thus, improving the patients' outcomes.
We are mainly focused on two aggressive forms of cancer, glioblastoma and triple-negative breast cancer.
One of our main goals is the study of the deadliest brain cancer, Glioblastoma. This cancer is characterized for its dismal prognosis, due to resistance to current treatments (temozolomide) and the presence of a persistent population of cells (Glioma Stem Cells).
Triple Negative Breast Cancer
Triple Negative Breast Cancer (TNBC) is characterized by the absence of ER, PR and HER2 markers, and is the subtype of Breast Cancer with the lowest survival, due to the lack of specific treatments for this tumors.
In the last years immunotherapy has emerged as a potential treatment for TNBC, but it is not effective in all patients. One of our main objectives is to identify biomarkers that allow the stratification of patients which will respond to immunotherapy and patients which will not.
The Fundación Contigo supports a project to study triple-negative breast cancer
This study may lead us to unveil the immune-evasion mechanisms that are responsible for Immunotherapy resistance in TNBC.
Our group has been awarded with the Impetus Call, which will support the first research project of Pere Llinàs-Arias as a principal investigator
This project aims to generate an epigenetic-based score to predict the metastasic risk in TNBC.